Department of Medicine, Federal University of Minas Gerais, Belo Horizonte, Brazil; Department of Medicine, Division of Endocrinology, College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
Annu Rev Med. 2011;62:307-22. doi: 10.1146/annurev-med-061709-145401.
Although safe and effective agents are currently available to treat osteoporosis, fragility fractures remain a significant problem worldwide. Recent improvements in the understanding of the cellular, biochemical, and molecular pathways of bone biology have led to the development of newer agents to treat osteoporosis, which may lead to further improvements in outcomes. In this review, we summarize the most recent advances in the field, including new modes of administration of existing drug classes, various approaches to combination therapy, and drugs with novel mechanisms of action to treat osteoporosis.
虽然目前有安全有效的药物可用于治疗骨质疏松症，但脆性骨折仍然是全球范围内的一个重大问题。对骨生物学的细胞、生化和分子途径的理解的最新进展，导致了治疗骨质疏松症的新药物的开发，这可能会进一步改善治疗效果。在这篇综述中，我们总结了该领域的最新进展，包括现有药物类别的新给药方式、各种联合治疗方法以及具有新作用机制的药物治疗骨质疏松症。
